萆苓祛痛方对糖尿病痛风大鼠骨骼肌组织SIRT3蛋白表达及URAT1 mRNA的影响

李中南; 邢艳阳; 周媛媛; 马淑红; 邢宇婷; 窦德梅; 方朝晖

doi:10.13422/j.cnki.syfjx.20191903

您当前的位置：

首页 >

文章列表页 >

萆苓祛痛方对糖尿病痛风大鼠骨骼肌组织SIRT3蛋白表达及URAT1 mRNA的影响

药理 | 更新时间：2021-02-09

- 萆苓祛痛方对糖尿病痛风大鼠骨骼肌组织SIRT3蛋白表达及URAT1 mRNA的影响
- Effect of Biling Qutong Prescription on SIRT3 Protein Expression and URAT1 mRNA in Skeletal Muscle of Diabetic Gout Rats
- 中国实验方剂学杂志 2019年25卷第21期页码：25-31
- 作者机构：
  
  1.安徽中医药大学　第一附属医院，合肥　 230031；
  2.安徽中医药大学　研究生院，合肥　 230038
- 作者简介：
  
  李中南，主任医师，硕士生导师，从事内分泌代谢病研究，Tel：0551-62850012，E-mail：lzn5151307@sohu.com
- 基金信息：
  
  国家中医临床研究基地业务建设科研专项(JDZX2012004);安徽省自然科学基金项目(1708085QH213)
- DOI：10.13422/j.cnki.syfjx.20191903
  中图分类号： R2-0; R22; R285.5; R289
- 收稿日期：2019-02-18，
  
  网络出版日期：2019-06-19，
  
  纸质出版日期：2019-11-05
- 稿件说明：
移动端阅览
李中南, 邢艳阳, 周媛媛, 等. 萆苓祛痛方对糖尿病痛风大鼠骨骼肌组织SIRT3蛋白表达及URAT1 mRNA的影响[J]. 中国实验方剂学杂志, 2019,25(21):25-31.

Zhong-nan LI, Yan-yang XING, Yuan-yuan ZHOU, et al. Effect of Biling Qutong Prescription on SIRT3 Protein Expression and URAT1 mRNA in Skeletal Muscle of Diabetic Gout Rats[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(21): 25-31.
李中南, 邢艳阳, 周媛媛, 等. 萆苓祛痛方对糖尿病痛风大鼠骨骼肌组织SIRT3蛋白表达及URAT1 mRNA的影响[J]. 中国实验方剂学杂志, 2019,25(21):25-31. DOI： 10.13422/j.cnki.syfjx.20191903.

Zhong-nan LI, Yan-yang XING, Yuan-yuan ZHOU, et al. Effect of Biling Qutong Prescription on SIRT3 Protein Expression and URAT1 mRNA in Skeletal Muscle of Diabetic Gout Rats[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(21): 25-31. DOI： 10.13422/j.cnki.syfjx.20191903.

摘要

目的：

探讨萆苓祛痛方对糖尿病痛风大鼠骨骼肌组织去乙酰化酶3(SIRT3)蛋白表达及尿酸盐转运体1(URAT1) mRNA的影响。

方法：

选择健康雄性大鼠40只，除正常组外，其余组予高脂饲料喂养并联合小剂量链脲佐菌素(STZ)溶液40 mg·kg

－1

腹腔注射1次，以血糖≥16.7 mmol·L

－1

，为糖尿病模型。4 d后关节腔注射5%尿酸钠溶液1次，诱导痛风模型，模型成功后，分为萆苓祛痛方组(萆苓组，10 g·kg

－1

)，吲哚美辛组(5 mg·kg

－1

)，吡格列酮组(10 mg·kg

－1

)，均连续给药21 d，正常组、模型组予等量生理盐水；采用蛋白免疫印迹法(Western blot)测定骨骼肌组织SIRT3蛋白表达；实时荧光定量聚合酶链式反应(Real-time PCR)检测骨骼肌组织URAT1 mRNA表达，并进行病理检查，取血测定血糖(GLU)，血尿酸(UA)及C反应蛋白(CRP)含量。

结果：

与正常组比较，模型组GLU，UA及CRP明显升高(

0.01)；与模型组比较，萆苓组、吡格列酮组血糖下降(

0.05)；各药物组UA及CRP明显下降(

0.01)。与正常组比较，模型组骨骼肌SIRT3蛋白表达量显著降低(

0.01)；与模型组比较，萆苓组骨骼肌SIRT3蛋白表达量显著提高(

0.01)，与西药组比较无明显差异；条带图的结果同样显示，与正常组比较，模型组表达亮度明显减弱，药物组表达亮度明显增强；与正常组比较，模型组关节组织URAT1 mRNA相对表达量明显升高(

0.01)；与模型组比较，各药物组URAT1 mRNA相对表达量显著下调(

0.01)。电泳图同样提示，正常组表达亮度减弱，模型组表达亮度显著增强，萆苓组、西药组表达亮度明显减弱。关节病理提示，与正常组比较，模型组大鼠关节病理损伤严重，可见大量炎细胞浸润及纤维增生，滑膜细胞变性、坏死。与模型组比较，萆苓祛痛方关节病变程度明显减低，见少量炎细胞浸润，滑膜上皮轻度增生。

结论：

具有泻浊解毒通络作用的萆苓祛痛方可显著提高糖尿病痛风大鼠骨骼肌组织SIRT3的蛋白表达量，下调URAT1 mRNA的表达量，减轻骨骼肌组织病理损伤，减低血清炎症因子CRP的含量，降低模型大鼠的血糖、血尿酸水平，有保护关节功能的作用。

Abstract

Objective:

To observe the effect of phlegm and blood stasis on the expressions of sirtuin 3(SIRT3)protein and urate transporter 1(URAT1) mRNA in skeletal muscle of diabetic rats with gout.

Method:

The 40 healthy rats

excepting the normal group

the remaining groups were fed with high-fat diet combined with low-dose streptozotocin solution (40 mg·kg

-1

) once a day

with blood glucose "16.7 mmol·L

-1

" as the criterion for the diabetes model. After 4 days

the 5%sodium urate solution was injected into the joint cavity once to induce the gout model. After the successful modeling

the Biling group (10 g·kg

-1

)

the indomethacin group (5 mg·kg

-1

) and the pioglitazone group (10 mg·kg

-1

) continued to be administered for 21 days. The normal group and the model group were given the same amount of normal saline. The expression of SIRT3 protein in skeletal muscle tissue was determined by Western blot

URAT1 mRNA expression in bone tissue was detected by quantitative real-time fluorescence polymerase chain reaction(Real-time PCR)

and blood was collected to measure blood glucose (GLU)

blood uric acid (UA) and C-reactive protein (CRP).

Result:

Compared with the normal group

GLU

UA and CRP in the model group were significantly increased (

0.01). Compared with the model group

GLU in the Biling group and the pioglitazone group were decreased

and UA and CRP in the medicine group were significantly decreased (

0.05

0.01). Compared with the normal group

the expression of SIRT3 protein in the skeletal muscle of the model group was significantly decreased (

0.01)

while the expression of SIRT3 protein in the skeletal muscle of the Biling group was significantly increased after administration (

0.01). Compared with the model group

the expression of SIRT3 protein in the skeletal muscle of the sputum group was significantly increased (

0.01)

with no significant difference from the western medicine group. The results of the strip chart also showed that compared with the model group

the expression brightness of the model group was significantly weakened

while the expression brightness of the drug group was significantly enhanced. Compared with the normal group

the relative expression of joint URAT1 mRNA in the model group was significantly increased (

0.01). Compared with the model group

the relative expression of URAT1 mRNA in each drug group was significantly down-regulated (

0.01). The results of the strip chart also showed that expression brightness of the normal group was the weakest

while that of the model group was the highest

and the expression brightness of the Biling group and the western medicine group was significantly weakened. Joint pathology suggested that compared with the normal group

the pathological damage of the joints in the model group was severe

with a large number of inflammatory cell infiltration and fibrosis

synovial cell degeneration and necrosis. Compared with the model group

the degree of joint disease was significantly reduced after treatment with Biling Qutong prescription

with only a small amount of inflammatory cell infiltration and mild hyperplasia in synovial epithelium.

Conclusion:

Biling Qutong prescription with effects in purging turbidity

detoxifying and dredging collaterals can significantly reduce the content of serum inflammatory factor CRP

significantly increase the protein expression of SIRT3 in skeletal muscle tissue of model rats

lower the content of URAT1 mRNA

reduce the blood glucose and blood uric acid levels in diabetic gout rats

and protect joints.

关键词

Keywords

references

梅长林，葛均波，邹和建，等．中国高尿酸血症相关疾病诊疗多学科专家共识 [J]．中华内科杂志， 2017 ， 36 ( 3 )： 235 - 244 ．

贺映侠，朱虹．黄芪多糖对2型糖尿病大鼠骨骼肌氧化应激水平及SIRT3表达的影响 [J]．中国老年学杂志， 2018 ， 38 ( 12 )： 3023 - 3025 ．

刘安宁，张高生，黄晶，等．津力达颗粒对2型糖尿病大鼠骨骼肌氧化应激水平以及SIRT3表达的影响 [J]．临床和实验医学杂志， 2017 ， 16 ( 4 )： 323 - 325 ．

祝艳林，甘华． SIRT3在尿酸诱导的肾小球系膜细胞转分化中的表达变化及意义 [J]．重庆医科大学学报， 2015 ， 40 ( 6 )： 865 - 869 ．

李懋．尿酸转运蛋白表达变化与糖尿病患者合并高尿酸血症的关系及其机制研究 [D]．兰州：甘肃中医药大学， 2015 ．

邢艳阳，李中南．李中南从浊毒瘀论治痛风经验举隅 [J]．山西中医， 2018 ， 34 ( 7 )： 4 - 6 ．

燕娟，郭巍伟，梁执群，等． 2型糖尿病大鼠模型的建立及其验证 [J]．临床和实验医学志， 2009 ， 8 ( 4 )： 5 - 6 ．

徐权毅，管云枫，徐添颖，等．痛风性关节炎大鼠的制备及三种关节肿胀度检测方法的比较 [J]．第二军医大学学报， 2007 ， 28 ( 8 )： 906 - 908 ．

郭玉星，熊辉，易法银，等．蠲痹历节清方对改良痛风性关节模型大鼠滑膜的TLR4，NF-κB，PPARγ的影响 [J]．中国实验方剂学杂志， 2018 ， 24 ( 23 )： 126 - 133 ．

左秀玲，朴金龙，薛丰田，等．黄连素对2型糖尿病大鼠血脂调节作用及对IL-6、IL-10及CRP水平的影响 [J]．陕西中医， 2018 ， 39 ( 8 )： 1001 - 1003 ．

李中南，石国彬，刘剑，等．萆苓祛痛方治疗2型糖尿病合并痛风临床观察 [J]．中国中医急症， 2010 ， 19 ( 9 )： 1487，1507 ．

黄思帆，宋海曲．吡格列酮对早期2型糖尿病患者糖脂代谢及胰岛功能指标的影响 [J]．中外医疗， 2017 ， 36 ( 33 )： 120-121，124 ．

彭湾湾，曾姣娥．吡格列酮、胰岛素对初诊2型糖尿病患者血尿酸及1，5-脱水葡萄糖醇的影响 [J]．长江大学学报：自然科学版， 2016 ， 13 ( 12 )： 5-7，3 ．

汪俊，李中南，李莉，等．萆苓祛痛方对糖尿病痛风模型大鼠血糖、血尿酸的影响及其抗炎作用的研究 [J]．中国中医药科技， 2012 ， 19 ( 2 )： 117 - 119 ．

李中南，邢艳阳，邢宇婷，等．泻浊解毒通络法对糖尿病痛风模型大鼠血清FOXOL、VCAM-1及肾脏病理的影响 [J]．上海中医药杂志， 2018 ， 52 ( 11 )： 75 - 79 ．

王冬平，曾臣．实验动物血液生理生化参考手册 [M]．北京：科学出版社， 2011 ， 35 - 36 ．

刘金畅，王涛．萆薢、土茯苓治疗高尿酸血症研究进展 [J]．辽宁中医药大学学报， 2018 ， 20 ( 1 )： 79 - 81 ．

孙红，王少明，庄捷，等．土茯苓等中药抑制URAT1表达及降尿酸作用筛选研究 [J]．中国临床药理学与治疗学， 2012 ， 17 ( 4 )： 403 - 407 ．

钱增堃，崔凡，凌云熹，等．泽泻多糖对糖尿病大鼠肝脏糖脂代谢的影响 [J]．中国实验方剂学杂志， 2018 ， 24 ( 11 )： 117 - 125 ．

马懿，阮云军，王玉筵，等．白藜芦醇苷通过上调SIRT1抑制氧化低密度脂蛋白诱导的THP-1巨噬细胞增殖和炎性因子表达 [J]．细胞与分子免疫学杂志， 2018 ， 34 ( 3 )： 193 - 198 ．

黄春林，朱晓新．中药药理与临床手册 [M]．北京：人民卫生出版社， 2006 ： 423-425，565-566 ．

陈光亮，朱立然，那莎，等．萆薢总皂苷对大鼠慢性高尿酸血症和肾小管尿酸转运体1表达的影响 [J]．中国中药杂志， 2013 ， 38 ( 14 )： 2348 - 2353 ．

李嘉诚，吴岚，蔡同凯，等．黄柏化学成分及其药理作用研究进展 [J]．药学实践杂志， 2018 ， 36 ( 5 )： 389-391，398 ．

吴福林，周柏松，董庆海，等．土鳖虫的药理、药化及其临床的研究进展 [J]．特产研究， 2018 ， 40 ( 3 )： 67 - 74 ．

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

萆苓祛痛方对2型糖尿病合并痛风性关节炎患者P2X7R、NLRP3、FN及肝脂肪变性的影响